The report The Hepatitis Market Outlook to 2016 provides comprehensive coverage of the hepatitis market, incorporating a detailed epidemiological analysis. The report analyzes current leading brands, and profiles leading players in the hetpatitis market.

1. The Hepatitis Market Outlook to 2016
Published:September 2011
No.Of Pages:124
Price:US $ 3835
The report The Hepatitis Market Outlook to 2016 provides comprehensive coverage of the
hepatitis market, incorporating a detailed epidemiological analysis. The report analyzes
current leading brands, and profiles leading players in the hetpatitis market. It also
identifies products in late stage development and forecasts their expected sales
performance.
Features and benefits
* Understand how recent events are affecting the performance of major products, and how
their marketers are confronting competitive market changes.
* Compare the franchises of the leading companies in the hepatitis market, and understand
how the market share of these companies will change.
* Evaluate pipeline compounds for the treatment of hepatitis and determine which products
will provide the greatest revenue growth.
* Understand the market dynamics and interactions between the key drug classes used in
the treatment of hepatitis.
* Forecast the performance of the leading marketed and pipeline products through to 2016.
Highlights
The launch of Incivek and Victrelis indicated for the treatment of hepatitis C, is anticipated
to change the treatment modality. The drugs are estimated to rapidly reach their peak sales
by 2012-13 due to their superior therapeutic profile compared to the currently marketed
products.
A strong market opportunity exists in patients less responsive to current hepatitis
treatment, including adults over 40 years of age, individuals with chronic renal disease and
individuals with HIV. The treatment-failure population, representing approximately 40% of
the total hepatitis C infected population, also presents a significant opportunity.
Roche was the global market leader in the treatment of hepatitis with a market share of
over 25%. Roche's performance was driven by its hepatitis C products, Copegus and
Pegasys. These products represent the current standard of care in this indication where they
compete strongly with Pegintron and Rebetol of Merck and Co.
Your key questions answered
* Who were the leading players in the hepatitis market in 2010 and which products were
driving their performance?
* What are the current market leading products in hepatitis treatment and how will their
market position change during the forecast period?

2. * Which of the seven major markets have the greatest market potential for hepatitis
therapy?
* How will the launch of Victrelis and Incivek impact upon the hepatitis C market?
Table Of Contents
* About the author
o Disclaimer
* EXECUTIVE SUMMARY
o Overview and epidemiology of hepatitis
o Global market analysis
o Pipeline analysis
o Competitive landscape
* Overview and epidemiology of hepatitis
o Summary
o Introduction
+ Hepatitis A
+ Hepatitis B
+ Hepatitis C
+ Hepatitis D
+ Hepatitis E
* Global market analysis
o Summary
o Introduction
o Market analysis by country
o Market analysis by drug class
o Leading brand dynamics

3. + Pegasys (peginterferon alfa-2a) – Roche
+ Hepatitis Vaccines – GSK
+ Baraclude (entecavir) – BMS
+ PegIntron (peginterferon alfa-2b) – Merck
+ Viread (tenofovir disoproxil fumarate) – Gilead Sciences
+ Copegus (ribavirin) – Roche
+ Rebetol (ribavirin) – Merck
+ Hepsera (adefovir dipivoxil) – Gilead
o A new era of treatment for Hepatitis C virus infection
+ Protease inhibitors (PIs)
+ The competition between Incivek and Victrelis
+ Factors governing the market space of Incivek and Victrelis
+ Product life cycle and forecast
o Hepatitis market drivers, challenges, and resistors
+ Launch of novel drugs for HCV treatment will promote revenue sales growth
+ Increased awareness of hepatitis will create a short to medium term sales
increase
+ Challenges in bridging the treatment gap impedes forecast market uptake
+ Warehoused patients seeking new treatment options will temporarily create
demand
+ Drugs with reduced adverse effects change the treatment modality
+ Launch of biosimilars and generics will slow market growth
+ The WHO’s approval of the SFDA’s vaccine regulation will increase low cost
vaccine supply
+ Increasing HIV-HCV/HBV co-infection rates if not reduced will affect sales
growth

4. o Key events
+ The FDA grants fast track status to Pharmasset’s PSI-7977 for the treatment
of HCV
+ Development program for therapeutic intranasal vaccine for treatment of
hepatitis B
+ Novartis discontinues the development of Joulferon/Zalbin on safety concerns
+ GSK signs microRNA deal with Regulus for HCV
+ Government initiatives to curb the incidence of hepatitis
+ Vertex collaborates with Alios for hepatitis portfolio
o Biosimilars and generics
o Leading hepatitis drugs sales forecast
* Pipeline analysis
o Summary
o Introduction
o Key trends in hepatitis R&D
+ Product differentiation will hold the key to success in the hepatitis market
+ Multi-billion dollar opportunity for a successful drug class
+ The treatment-failure population presents a significant opportunity
+ End stage renal disease (ESRD) patients present high potential for vaccines
+ Despite the introduction of novel treatments, the SOC for hepatitis C will not
change
o Profiles of the key pipeline products
+ TMC435 – Medivir/J&J
+ BI 201335 – Boehringer Ingelheim
+ Vaniprevir (MK-7009) – Merck

5. + Debio 025 – Novartis/Debiopharm
+ Danoprevir (ITMN-191/RG7227) – Roche
+ RG-7128 – Roche/ Pharmasset
+ ABT-450 – Abbott/Enanta
+ BMS-790052 – Bristol-Myers Squibb
+ GS-9190 (Tegobuvir) – Gilead Sciences
+ GS-9256 – Gilead Sciences
+ ACH-1625 – Achillion
* Competitive landscape
o Summary
o Introduction
o Competitive positioning of the leading players in the global hepatitis market
o Roche
+ Marketed product portfolio
+ Pipeline analysis
+ Strategic and growth analysis
o GSK
+ Marketed product portfolio
+ Pipeline analysis
+ Strategic and growth analysis
o Merck & Co.
+ Marketed product portfolio
+ Pipeline analysis
+ Strategic and growth analysis

6. o Gilead
+ Marketed product portfolio
+ Pipeline analysis
+ Strategic and growth analysis
o Bristol-Myers Squibb
+ Marketed product portfolio
+ Pipeline analysis
+ Strategic and growth analysis
* Appendix
o Scope
o Methodology
+ Epidemiology
+ Market forecast
o Glossary/Abbreviations
+ Abbreviations
o Bibliography/References
* TABLES
o Table: Worldwide endemicity of HAV infection
o Table: Segmentation of regions by prevalence of hepatitis B
o Table: Prevalence of hepatitis B by country
o Table: Forecast epidemiology of chronic hepatitis B to 2016
o Table: Prevalence of hepatitis C infection by country
o Table: Forecast epidemiology of hepatitis C in the 7MM to 2016
o Table: Global hepatitis market by region ($m), 2010

7. o Table: Hepatitis market by drug class ($m), 2010
o Table: Leading brands in the global hepatitis market ($m), 2010
o Table: Result of SPRINT-2 clinical trial in different cohorts
o Table: Efficacy comparison of Incivek and Victrelis in Phase III study
o Table: Forecast sales of Incivek and Victrelis, 2010-16
o Table: Impact of drivers and challenges in hepatitis market to 2016
o Table: Adverse effects associated with different treatment modalities
o Table: Leading hepatitis brands sale forecast ($m), 2010-16
o Table: An overview of TMC435
o Table: An overview of BI 201335
o Table: An overview of vaniprevir
o Table: An overview of Debio 025
o Table: An overview of danoprevir
o Table: An overview of RG7128
o Table: An overview of ABT-450
o Table: An overview of BMS-790052
o Table: An overview of GS-9190
o Table: An overview of GS-9256
o Table: An overview of ACH-1625
o Table: Leading players in the global hepatitis market ($m), 2010
o Table: Performance of Roche's hepatitis products ($m), 2010
o Table: Roche’s hepatitis R&D pipeline, April 2011
o Table: Performance of GSK's hepatitis products ($m), 2010
o Table: GSK’s hepatitis R&D pipeline, Feb 2011

8. o Table: Performance of Merck's hepatitis products ($m), 2010
o Table: Merck’s hepatitis R&D pipeline, Feb 2011
o Table: Performance of Gilead's hepatitis products ($m), 2010
o Table: Gilead’s hepatitis R&D pipeline, Feb 2011
o Table: Performance of BMS’ hepatitis products ($m), 2010
o Table: BMS’ hepatitis R&D pipeline, Feb 2011
* FIGURES
o Figure: Evolution of HCV treatment modalities
o Figure: Perceptual position of Incivek and Victrelis
o Figure: Competitive position of Incivek and Victrelis
o Figure: Product life cycle of Incivek and Victrelis
o Figure: Forecast sales of Incivek and Victrelis to 2016
o Figure: Sales of the leading players in the global hepatitis market ($m), 2006-2010
o Figure: Response of patients to drug therapy
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog